Biopsy; Cancer Staging; Endometrial Cancer; Magnetic Resonance Imaging; Risk Assessment; Sentinel Lymph Node; Female; Humans; Lymph Node Excision; Medical Oncology; Neoplasm Staging; Retrospective Studies; Sentinel Lymph Node Biopsy; Endometrial Neoplasms/diagnostic imaging; Endometrial Neoplasms/pathology; Endometrial Neoplasms/surgery; Endometrial Neoplasms; Oncology; Obstetrics and Gynecology; General Medicine
Abstract :
[en] [en] OBJECTIVE: To evaluate the concordance between preoperative European Society for Medical Oncology (ESMO)-European Society of Gynaecological Oncology (ESGO)-European SocieTy for Radiotherapy and Oncology (ESTRO) risk classification in early-stage endometrial cancer (EC) assessed by biopsy and magnetic resonance imaging (MRI) with this classification based on histology of surgical specimen.
METHODS: This bicentric retrospective study included women diagnosed with early-stage EC (≤stage II) who had a complete preoperative assessment and underwent a surgical management from January 2011 to December 2018. Patients were preoperatively classified into 3 degrees of risk of lymph node (LN) involvement based on biopsy and MRI. Based on final histological report, patients were re-classified using the preoperative classification. Concordance between the preoperative assessment and definitive histology was calculated with weighted Cohen's kappa coefficient.
RESULTS: A total of 333 women were included and kappa coefficient of preoperative risk classification was 0.49. The risk was underestimated and overestimated in 37% and 10% of cases, respectively. Twenty-nine percent of patients had an incomplete LN staging according to the degree of risk of re-classification. The observed discordance in the risk classification was attributed to MRI in 75% of cases, to biopsy in 18% and in 7% to both (p<0.001). Kappa coefficient for concordance was 0.25 for MRI and 0.73 for biopsy.
CONCLUSION: Concordance between preoperative ESMO-ESGO-ESTRO risk classification and final histology is weak. Given that the risk was underestimated in the majority of patients wrongly classified, sentinel LN procedure instead of no LN dissection could be an option offered to preoperative low-risk patients to decrease the indication of second surgery for re-staging and/or to avoid toxicity of adjuvant radiotherapy.
Disciplines :
Oncology
Author, co-author :
Daix, Manon ; Université de Liège - ULiège > Département des sciences cliniques > Anesthésie et réanimation ; Department of Surgical Oncology, Institut Universitaire du Cancer de Toulouse - Institut Claudius Regaud, Oncopole, Toulouse, France ; Department of Gynecology, Centre Hospitalier Chrétien - Mont Légia, Liège, Belgium. manondaix89@gmail.com
Angeles, Martina Aida ; Department of Surgical Oncology, Institut Universitaire du Cancer de Toulouse - Institut Claudius Regaud, Oncopole, Toulouse, France
Migliorelli, Federico ; Department of Gynecology, Centre Hospitalier Intercommunal des Vallées de l'Ariège, Saint Jean de Verges, France
Kakkos, Athanasios ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique
Martinez Gomez, Carlos ; Department of Surgical Oncology, Institut Universitaire du Cancer de Toulouse - Institut Claudius Regaud, Oncopole, Toulouse, France ; Inserm CRCT, Toulouse, France
Delbecque, Katty ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'anatomie et cytologie pathologiques
Mery, Eliane ; Department of Pathology, Institut Universitaire du Cancer de Toulouse - Institut Claudius Regaud, Oncopole, Toulouse, France
Tock, Stéphanie ; Department of Gynecology, Centre Hospitalier Chrétien - Mont Légia, Liège, Belgium
Gabiache, Erwan ; Department of Medical Imaging, Institut Universitaire du Cancer de Toulouse - Institut Claudius Regaud, Oncopole, Toulouse, France
De Cuypere, Marjolein ; Université de Liège - ULiège > Département des sciences cliniques
Goffin, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique (CHR)
Martinez, Alejandra ; Department of Surgical Oncology, Institut Universitaire du Cancer de Toulouse - Institut Claudius Regaud, Oncopole, Toulouse, France ; Inserm CRCT, Toulouse, France
Ferron, Gwénaël ; Department of Surgical Oncology, Institut Universitaire du Cancer de Toulouse - Institut Claudius Regaud, Oncopole, Toulouse, France ; Inserm CRCT, Toulouse, France
Kridelka, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique
Martina Aida Angeles acknowledges the grant support from “la Caixa” Foundation, Barcelona (Spain), ID 100010434. The fellowship code is LCF/BQ/EU18/11650038.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30. PUBMED | CROSSREF
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGOESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer 2016;26:2-30. PUBMED | CROSSREF
Querleu D, Darai E, Lecuru F, Rafii A, Chereau E, Collinet P, et al. Primary management of endometrial carcinoma. Joint recommendations of the French society of gynecologic oncology (SFOG) and of the French college of obstetricians and gynecologists (CNGOF). Gynecol Obstet Fertil Senol 2017;45:715-25. PUBMED | CROSSREF
Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: International Agency for Research on Cancer; 2014.
Body N, Lavoué V, De Kerdaniel O, Foucher F, Henno S, Cauchois A, et al. Are preoperative histology and MRI useful for classification of endometrial cancer risk? BMC Cancer 2016;16:498. PUBMED | CROSSREF
Groff B, Pouget O, Stoll F, Mathelin C, Baldauf JJ, Akladios CY. Pertinence of the preoperative exploration in the evaluation of the risk of lymph node metastasis in endometrial cancer. Gynecol Obstet Fertil 2014;42:92-6. PUBMED | CROSSREF
Raimond E, Canlorbe G, Bendifallah S, Hudry D, Selvi F, Ballester M, et al. Endometrial carcinoma. Application of the guidelines of 2010: multicentre trial. Bull Cancer 2014;101:703-13. PUBMED | CROSSREF
Lavaud P, Fedida B, Canlorbe G, Bendifallah S, Darai E, Thomassin-Naggara I. Preoperative MR imaging for ESMO-ESGO-ESTRO classification of endometrial cancer. Diagn Interv Imaging 2018;99:387-96. PUBMED | CROSSREF
Arsène E, Bleu G, Merlot B, Boulanger L, Vinatier D, Kerdraon O, et al. Implications of a two-step procedure in surgical management of patients with early-stage endometrioid endometrial cancer. J Gynecol Oncol 2015;26:125-33. PUBMED | CROSSREF
Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Giugliano D. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine 2014;45:28-36. PUBMED | CROSSREF
Zhang Y, Liu H, Yang S, Zhang J, Qian L, Chen X. Overweight, obesity and endometrial cancer risk: results from a systematic review and meta-analysis. Int J Biol Markers 2014;29:e21-9. PUBMED | CROSSREF
Kinkel K, Forstner R, Danza FM, Oleaga L, Cunha TM, Bergman A, et al. Staging of endometrial cancer with MRI: guidelines of the European Society of Urogenital Imaging. Eur Radiol 2009;19:1565-74. PUBMED | CROSSREF
McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 2012;22:276-82. PUBMED | CROSSREF
Creutzberg CL. GOG-99: ending the controversy regarding pelvic radiotherapy for endometrial carcinoma? Gynecol Oncol 2004;92:740-3. PUBMED | CROSSREF
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 2019;20:1273-85. PUBMED | CROSSREF
Tatebe K, Hasan Y, Son CH. Adjuvant vaginal brachytherapy and chemotherapy versus pelvic radiotherapy in early-stage endometrial cancer: outcomes by risk factors. Gynecol Oncol 2019;155:429-35. PUBMED | CROSSREF
Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev 2017;10:CD007585. PUBMED | CROSSREF
Visser NCM, Reijnen C, Massuger LFAG, Nagtegaal ID, Bulten J, Pijnenborg JMA. Accuracy of endometrial sampling in endometrial carcinoma: a systematic review and meta-analysis. Obstet Gynecol 2017;130:803-13. PUBMED | CROSSREF
Huang GS, Gebb JS, Einstein MH, Shahabi S, Novetsky AP, Goldberg GL. Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. Am J Obstet Gynecol 2007;196:243.e1-243.e5. PUBMED | CROSSREF
Zamani F, Goodarzi S, Hallaji F, Zamiri A, Deilami T, Malek M, et al. Diagnostic value of pelvic MRI for assessment of the depth of myometrial invasion and cervical involvement in endometrial cancer: comparison of new versus old FIGO staging. Iran J Radiol 2012;9:202-8. PUBMED | CROSSREF
Haldorsen IS, Salvesen HB. Staging of endometrial carcinomas with MRI using traditional and novel MRI techniques. Clin Radiol 2012;67:2-12. PUBMED | CROSSREF
Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010;375:1165-72. PUBMED | CROSSREF
Kim HS, Suh DH, Kim MK, Chung HH, Park NH, Song YS. Systematic lymphadenectomy for survival in patients with endometrial cancer: a meta-analysis. Jpn J Clin Oncol 2012;42:405-12. PUBMED | CROSSREF
Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100:1707-16. PUBMED | CROSSREF
Barton DPJ, Naik R, Herod J. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomized study. Int J Gynecol Cancer 2009;19:1465. PUBMED | CROSSREF
Sharma C, Deutsch I, Lewin SN, Burke WM, Qiao Y, Sun X, et al. Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer. Am J Obstet Gynecol 2011;205:562.e1-562.e9. PUBMED | CROSSREF
Klopp AH, Yeung AR, Deshmukh S, Gil KM, Wenzel L, Westin SN, et al. Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG oncology-RTOG 1203. J Clin Oncol 2018;36:2538-44. PUBMED | CROSSREF
Rossi EC, Kowalski LD, Scalici J, Cantrell L, Schuler K, Hanna RK, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 2017;18:384-92. PUBMED | CROSSREF
Ballester M, Dubernard G, Lécuru F, Heitz D, Mathevet P, Marret H, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol 2011;12:469-76. PUBMED | CROSSREF
Lecointre L, Lodi M, Faller É, Boisramé T, Agnus V, Baldauf JJ, et al. Diagnostic accuracy and clinical impact of sentinel lymph node sampling in endometrial cancer at high risk of recurrence: a meta-analysis. J Clin Med 2020;9:3874. PUBMED | CROSSREF
Bendifallah S, Canlorbe G, Collinet P, Arsène E, Huguet F, Coutant C, et al. Just how accurate are the major risk stratification systems for early-stage endometrial cancer? Br J Cancer 2015;112:793-801. PUBMED | CROSSREF
Tuomi T, Pasanen A, Leminen A, Bützow R, Loukovaara M. Prediction of lymphatic dissemination in endometrioid endometrial cancer: comparison of three risk-stratification models in a single-institution cohort. Gynecol Oncol 2017;144:510-4. PUBMED | CROSSREF
Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 2018;29:1180-8. PUBMED | CROSSREF
Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancercombined analysis of the PORTEC cohorts. Clin Cancer Res 2016;22:4215-24. PUBMED | CROSSREF
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.